Immune Response to HPV Has Impact on Prognosis

Nivolumab demonstrates superiority over standard of care for head-and-neck cancer in phase III trial

The Groupe d’Oncologie Radiothérapie Tête Et Cou, also known as the Head and Neck Oncology and Radiotherapy Group or GORTEC, announced that the randomized phase III CheckMate -9KW/NIVOPOSTOP GORTEC 2018-01 trial evaluating nivolumab (Opdivo) as a post-operative treatment component for resected patients with locally advanced squamous cell carcinoma of head and neck with high risk of relapse met its primary endpoint of disease-free survival across all comers.

January 17, 2025

Vol.51 No.02

In Brief

LSU Health New Orleans receives $3.1M grant to study head-and-neck cancer incidence in people living with HIV

LSU Health New Orleans was awarded a five-year, $3.1 million grant from the National Institute of Dental and Craniofacial Research.

November 15, 2024

Vol.50 No.43

Clinical

Randomized trial failed to accrue, but data point to preoperative chemo as viable option in sinonasal cancer

If clinical research were anything like fly fishing, the scientific question that EA3163 trial attempted to answer might be considered “the one that got away”.

SU2C announces grants supporting research in six cancer types

Stand Up To Cancer announced grants to several teams of leading cancer investigators in support of cutting-edge research in a variety of cancers including head and neck, pediatric, pancreatic, breast, rectal, and gastro-esophageal cancers, as well as research focused on how the microbiome communicates with the immune system.

October 18, 2024

Vol.50 No.39

Clinical Roundup

Keytruda meets primary endpoint as perioperative treatment regimen in resected, locally advanced HNSCC

The phase III KEYNOTE-689 trial evaluating Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, as a perioperative treatment for patients newly diagnosed with stage 3 or 4A, resected, locally advanced head and neck squamous cell carcinoma met its primary endpoint of event-free survival.

October 11, 2024

Vol.50 No.38

Clinical Roundup

Mayo Clinic performs world’s first known successful total larynx transplant in a patient with active cancer

A multidisciplinary team of doctors at Mayo Clinic in Arizona performed the third known total larynx transplant in the U.S.

July 12, 2024

Vol.50 No.28

Immune Response to HPV Has Impact on Prognosis

YOU MAY BE INTERESTED IN

Nivolumab demonstrates superiority over standard of care for head-and-neck cancer in phase III trial

LSU Health New Orleans receives $3.1M grant to study head-and-neck cancer incidence in people living with HIV

Randomized trial failed to accrue, but data point to preoperative chemo as viable option in sinonasal cancer

SU2C announces grants supporting research in six cancer types

Keytruda meets primary endpoint as perioperative treatment regimen in resected, locally advanced HNSCC

Mayo Clinic performs world’s first known successful total larynx transplant in a patient with active cancer

Renew today!

Subscriber content

Never miss an issue!

Login